Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Phathom Pharmaceuticals to post earnings of ($1.06) per share and revenue of $27.91 million for the quarter.

Phathom Pharmaceuticals Price Performance

NASDAQ PHAT opened at $4.12 on Friday. Phathom Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $19.71. The stock has a market capitalization of $286.90 million, a P/E ratio of -0.72 and a beta of 0.35. The firm’s 50-day moving average is $5.17 and its two-hundred day moving average is $8.31.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PHAT. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Monday. Craig Hallum reaffirmed a “buy” rating on shares of Phathom Pharmaceuticals in a research report on Friday, March 7th. Guggenheim reiterated a “buy” rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. The Goldman Sachs Group lowered their price objective on shares of Phathom Pharmaceuticals from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $21.83.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.